2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.46

PP02.46 - Wenmei Su

Pdf Summary

This study investigates the effects of different sequences of radiotherapy (RT) and immunotherapy (IT) on the survival and efficacy in treating lung cancer. A cohort of 120 lung cancer patients was assessed, with participants divided into two groups: RT followed by IT and IT followed by RT. The primary goal was to understand how these sequences impact overall survival (OS), progression-free survival (PFS), and treatment response.<br /><br />Key findings from the analysis showed no significant differences in OS and PFS between groups overall. However, for patients receiving IT as a first-line treatment, OS improved when RT followed IT, with average survival times of 37.9 months for the RT to IT group compared to 30 months for the IT to RT group. Additionally, the objective response rate (ORR) was notably higher in the IT to RT group (69.5%) compared to the RT to IT group (31.3%).<br /><br />Patient outcomes were further assessed for adverse reactions, revealing no significant differences in toxicity between the groups. The research highlights that using IT initially can enhance OS when followed by RT, suggesting a potential advantage in sequence selection for treatment. Nonetheless, the broader variations in sequence outcomes require further investigation to confirm these results.<br /><br />Overall, the study underscores the need for more research to optimize treatment sequences, acknowledging that both RT and IT have demonstrated capabilities to enhance anti-tumor responses. Despite the promising findings, the variability in response hints at the complexity involved in treating lung cancer, emphasizing the potential for further personalization of therapy sequences to improve patient outcomes.

Keywords

lung cancer

radiotherapy

immunotherapy

treatment sequence

overall survival

progression-free survival

objective response rate

first-line treatment

adverse reactions

personalized therapy